Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.48 |
| ▸ | RAF1 | P04049 | 5/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3990762 | 0.85 | MAPK14 (0.57) | MAPK14MAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL3989293 | 0.84 | MAP2K3 (0.54) | MAPK14MAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL3993152 | 0.83 | MAPK14 (0.45) | MAPK14MAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL11633700 | 0.81 | MAPK14 (0.57) | MAPK14MAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL4558663 | 0.81 | MAPK14 (0.46) | MAPK14MAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL5782669 | 0.78 | MAPK14 (0.53) | MAPK14MAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL5613054 | 0.75 | MAPK14 (0.74) | MAPK14MAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL4413641 | 0.75 | MAPK14 (0.70) | MAPK14MAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL3993149 | 0.75 | MAPK14 (0.43) | MAPK14MAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL4065944 | 0.72 | MAPK14 (0.43) | MAPK14MAPK13RAF1MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582652-B2 | Suppression cytokines, tumor necrosis factor; melanoma | ELI LILLY AND COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1713805-B1 | KINASE INHIBITORS | LILLY CO ELI (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090036445-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036445-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | MAPK14 174/4885MAPK13 149/4885RAF1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.